Keywords: memory, pharma, starts, dosing, phase, study, mem

Memory Pharma starts dosing in Phase I study of MEM 3454

Article | 07 March 2005

Print This

US drug firm Memory Pharmaceuticals has commenced dosing in a Phase I study of MEM 3454, a partial agonist of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in